UK signs deals with Pfizer, BioNTech and Valneva to secure 90 million doses of possible COVID-19 vaccines

With no vaccine against COVID-19 developed yet, Britain now has three different types of vaccines under order and a total of 230 million doses potentially available.

Reuters July 20, 2020 16:01:28 IST
UK signs deals with Pfizer, BioNTech and Valneva to secure 90 million doses of possible COVID-19 vaccines

London: Britain has signed deals to secure 90 million doses of two possible COVID-19 vaccines from an alliance of Pfizer Inc and BioNTech, and French group Valneva, the business ministry said on Monday.

Britain secured 30 million doses of the experimental BioNTech/Pfizer vaccine, and a deal in principle for 60 million doses of the Valneva vaccine, with an option of 40 million more doses if it was proven to be safe, effective and suitable, the ministry said.

With no working vaccine against COVID-19 yet developed, Britain now has three different types of vaccines under order and a total of 230 million doses potentially available.

“This new partnership with some of the world’s foremost pharmaceutical and vaccine companies will ensure the UK has the best chance possible of securing a vaccine that protects those most at risk,” business minister Alok Sharma said.

Financial terms were not disclosed.

The deals follow a previously announced agreement with AstraZeneca for the firm to produce 100 million doses of its potential vaccine being developed in partnership with the University of Oxford.

Britain said it was the first such deal that Pfizer and BioNTech had agreed for the supply of their vaccine, which is being tested in early to mid-stage trials.

The firms are aiming to make up to 100 million doses by the end of this year and potentially more than 1.2 billion doses by the end of 2021 if the vaccine is successful.

It uses the so-called messenger RNA approach, in contrast to the more traditional, inactivated whole virus vaccine being developed by Valneva.

Valneva’s potential vaccine is still in pre-clinical trials, and the company is aiming to move into clinical trials by the end of 2020.

Britain also said on Monday it had secured treatments containing COVID-19 -neutralising antibodies from AstraZeneca to protect people who can’t be vaccinated.

Updated Date:

also read

Over 1.91 lakh healthcare, sanitary workers get COVID-19 vaccine jabs; no cases of post-vaccination hospitalisation, says Centre
India

Over 1.91 lakh healthcare, sanitary workers get COVID-19 vaccine jabs; no cases of post-vaccination hospitalisation, says Centre

The Union health ministry that the programme had been a "success" as no cases of post-vaccination hospitalisation had been reported as of 7 pm on Saturday

Centre orders 11 mn doses of Oxford-AstraZeneca vaccine from SII at Rs 210 each
India

Centre orders 11 mn doses of Oxford-AstraZeneca vaccine from SII at Rs 210 each

Doses of the vaccine, Covishield, will initially be shipped to 60 consignee points and will then be distributed to various vaccination centres across India

India has administered one million COVID-19 vaccines in just six days, says health ministry
India

India has administered one million COVID-19 vaccines in just six days, says health ministry

In a span of 24 hours, close to two lakh people were vaccinated across 3,512 sessions. A total of 27,920 sessions have been conducted so far, the ministry said